Genetics research platform discovering causal drug targets using Newfoundland's founder-effect population cohort.
Sequence Bio uses the genetic founder effects in Newfoundland and Labrador—combined with detailed family health histories—to identify true causal genetic signals of disease for drug target discovery. The platform pairs genetic data with deep clinical records to move from statistical association to causal evidence, helping pharmaceutical partners identify the right drug targets and predictors of treatment response from the start. The company collaborates with local healthcare providers and global life sciences partners to translate insights into medicines. Sequence Bio is a product of Sequence Bio.